ONTOX

The ONTOX project aims to develop new approach methodologies (NAMs) to better predict the toxic effects of chemicals on the human body. These methodologies will be designed to assess the risks of systemic repeated dose toxicity in a wide range of chemicals. The focus will be on assessing the impact on the liver, kidneys, and developing brain. This research has the potential to benefit various industries, including pharmaceuticals, cosmetics, food, and biocides.

The NAMs developed in the project will use a computational system based on state-of-the-art artificial intelligence (AI), which will mainly utilize various types of existing data such as biological, mechanistic, toxicological, epidemiological, physicochemical, and kinetic data. These data will be integrated into physiological maps, quantitative adverse outcome pathway (AOP) networks, and ontology frameworks. Any missing data will be addressed through targeted in vitro and in silico testing.

The evaluation and application of the NAMs will be carried out in collaboration with industrial and regulatory stakeholders to ensure maximum acceptance from end-users and regulatory bodies. This collaborative approach is expected to speed up the implementation of NAMs in risk assessment practices and assist in their commercialization.

The ONTOX project is expected to have a significant and lasting impact by reinforcing Europe’s leadership in developing, regulating, and applying animal-free methods for human risk assessment of chemicals.

Period:

2021 – 2026

Call:

H2020-SC1-BHC-2018-2020

Granting authority:

Funded from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 963845. ONTOX is part of the ASPIS project cluster (https://aspiscluster.eu/).


This project has received funding from the European Union’s Horizon Europe research and innovation programme (innovation action) under grant agreement No. 963845.